Company Performance Metrics
- Milton Brown: Co-Founder, Chief Executive Officer
Trocar Pharma develops small molecule therapeutics targeting severe public health threats across radiation mitigation, oncology, and chronic degenerative diseases. The company builds on a tissue-targeted platform that focuses on intercellular reactive oxygen species to reduce oxidative stress, counter apoptosis, and support stem cell regeneration.
Its lead compound, YK-4-250, is a patented small molecule designed to treat gastrointestinal acute radiation syndrome and mitigate cellular damage after high-dose radiation exposure. Beyond radiation countermeasures, Trocar Pharma advances oncology programs including small molecule BRCA-1 mimetics intended for breast, ovarian, and therapy-resistant cancers. The company also develops therapeutics for chronic kidney disease and lung fibrosis that modulate the renin angiotensin aldosterone system and upregulate ACE2 while reducing reactive oxygen species. Additional programs investigate approaches for emerging infectious diseases such as COVID-19 by modulating host inflammatory responses. Trocar Pharma supports its pipeline through collaborations with academic institutions and government research agencies.
